Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Holdings Raised by Winslow Capital Management LLC

Winslow Capital Management LLC lifted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,020,567 shares of the biopharmaceutical company’s stock after purchasing an additional 58,960 shares during the quarter. Winslow Capital Management LLC’s holdings in Alnylam Pharmaceuticals were worth $240,150,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Quantinno Capital Management LP increased its position in Alnylam Pharmaceuticals by 50.3% during the third quarter. Quantinno Capital Management LP now owns 3,366 shares of the biopharmaceutical company’s stock worth $926,000 after acquiring an additional 1,126 shares during the period. Kovitz Investment Group Partners LLC acquired a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at about $669,000. EP Wealth Advisors LLC bought a new position in Alnylam Pharmaceuticals in the 3rd quarter worth approximately $201,000. Orion Portfolio Solutions LLC raised its position in shares of Alnylam Pharmaceuticals by 14.8% during the third quarter. Orion Portfolio Solutions LLC now owns 3,541 shares of the biopharmaceutical company’s stock worth $974,000 after acquiring an additional 457 shares during the last quarter. Finally, MML Investors Services LLC lifted its position in Alnylam Pharmaceuticals by 5.7% during the 3rd quarter. MML Investors Services LLC now owns 3,086 shares of the biopharmaceutical company’s stock valued at $849,000 after purchasing an additional 166 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on ALNY. HC Wainwright reiterated a “buy” rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. Canaccord Genuity Group raised their target price on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a “buy” rating in a report on Friday, March 21st. Bank of America upped their price target on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a research note on Friday, March 21st. Needham & Company LLC reissued a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. Finally, William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. One analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $316.25.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the sale, the executive vice president now owns 12,881 shares of the company’s stock, valued at approximately $3,240,344.36. This represents a 10.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Phillip A. Sharp sold 11,250 shares of the stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock valued at $19,958,097 in the last three months. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $224.32 on Wednesday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The stock’s 50-day simple moving average is $256.07 and its 200 day simple moving average is $259.24. The firm has a market capitalization of $29.18 billion, a PE ratio of -103.37 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.